Compare · GPCR vs PFE
GPCR vs PFE
Side-by-side comparison of Structure Therapeutics Inc. (GPCR) and Pfizer Inc. (PFE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GPCR and PFE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- PFE is the larger of the two at $167.83B, about 111.9x GPCR ($1.50B).
- PFE has been more active in the news (14 items in the past 4 weeks vs 6 for GPCR).
- PFE has more recent analyst coverage (25 ratings vs 16 for GPCR).
- Company
- Structure Therapeutics Inc.
- Pfizer Inc.
- Price
- -
- -
- Market cap
- $1.50B
- $167.83B
- 1M return
- -
- +3.77%
- 1Y return
- -
- +13.79%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2023
- News (4w)
- 6
- 14
- Recent ratings
- 16
- 25
Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Latest GPCR
- SEC Form 10-Q filed by Structure Therapeutics Inc.
- Structure Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Structure Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
- Amendment: SEC Form SCHEDULE 13G/A filed by Structure Therapeutics Inc.
- Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference
- Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026
- CHIEF MEDICAL OFFICER Coll Crespo Blas covered exercise/tax liability with 10,626 units of Ordinary Shares, decreasing direct ownership by 8% to 258,228 units (SEC Form 4) (for tax liability)
- Structure Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management
- Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences
Latest PFE
- Pfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity Program
- Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
- FDA Approval for HYMPAVZI issued to PFIZER INC
- Pfizer downgraded by DZ Bank
- Pfizer Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Election Day Trading Splits the Benchmarks, With the Dow Lower and the Nasdaq Higher
- Chairman & CEO Bourla Albert was granted 20 units of Phantom Stock Units SSP (SEC Form 4)
- SEC Form 10-Q filed by Pfizer Inc.
- Pfizer Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance